Gliomatosis cerebri natural history, complications, and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 23: | Line 23: | ||
The median survival time of gliomatosis cerebri is 14 months.<ref name="pmid12325066">{{cite journal| author=Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB et al.| title=Gliomatosis cerebri: molecular pathology and clinical course. | journal=Ann Neurol | year= 2002 | volume= 52 | issue= 4 | pages= 390-9 | pmid=12325066 | doi=10.1002/ana.10297 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12325066 }} </ref> | The median survival time of gliomatosis cerebri is 14 months.<ref name="pmid12325066">{{cite journal| author=Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB et al.| title=Gliomatosis cerebri: molecular pathology and clinical course. | journal=Ann Neurol | year= 2002 | volume= 52 | issue= 4 | pages= 390-9 | pmid=12325066 | doi=10.1002/ana.10297 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12325066 }} </ref> | ||
Medial survival of patients who were treated with [[radiotherapy|whole brain radiotherapy]] alone is 13.7 months (range 1–35), whereas those who were treated with combined [[radiotherapy|whole brain radiation therapy]] and [[chemotherapy]] have a median survival of 26.14 months (range 6–42).<ref name="pmid22740882">{{cite journal| author=Rajz GG, Nass D, Talianski E, Pfeffer R, Spiegelmann R, Cohen ZR| title=Presentation patterns and outcome of gliomatosis cerebri. | journal=Oncol Lett | year= 2012 | volume= 3 | issue= 1 | pages= 209-213 | pmid=22740882 | doi=10.3892/ol.2011.445 | pmc=PMC3362440 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22740882 }} </ref> | |||
The prognosis of gliomatosis cerebri depends on the following:<ref name="pmid12325066">{{cite journal| author=Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB et al.| title=Gliomatosis cerebri: molecular pathology and clinical course. | journal=Ann Neurol | year= 2002 | volume= 52 | issue= 4 | pages= 390-9 | pmid=12325066 | doi=10.1002/ana.10297 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12325066 }} </ref><ref name="pmid21339680">{{cite journal| author=Brandão RA, de Carvalho GT, de Azeredo Coutinho CA, Christo PP, Santiago CF, Santos Mdo C et al.| title=Gliomatosis cerebri: diagnostic considerations in three cases. | journal=Neurol India | year= 2011 | volume= 59 | issue= 1 | pages= 122-5 | pmid=21339680 | doi=10.4103/0028-3886.76892 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21339680 }} </ref> | The prognosis of gliomatosis cerebri depends on the following:<ref name="pmid12325066">{{cite journal| author=Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB et al.| title=Gliomatosis cerebri: molecular pathology and clinical course. | journal=Ann Neurol | year= 2002 | volume= 52 | issue= 4 | pages= 390-9 | pmid=12325066 | doi=10.1002/ana.10297 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12325066 }} </ref><ref name="pmid21339680">{{cite journal| author=Brandão RA, de Carvalho GT, de Azeredo Coutinho CA, Christo PP, Santiago CF, Santos Mdo C et al.| title=Gliomatosis cerebri: diagnostic considerations in three cases. | journal=Neurol India | year= 2011 | volume= 59 | issue= 1 | pages= 122-5 | pmid=21339680 | doi=10.4103/0028-3886.76892 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21339680 }} </ref> | ||
Revision as of 15:20, 2 October 2015
|
Gliomatosis cerebri Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Gliomatosis cerebri natural history, complications, and prognosis On the Web |
|
American Roentgen Ray Society Images of Gliomatosis cerebri natural history, complications, and prognosis |
|
FDA on Gliomatosis cerebri natural history, complications, and prognosis |
|
CDC on Gliomatosis cerebri natural history, complications, and prognosis |
|
Gliomatosis cerebri natural history, complications, and prognosis in the news |
|
Blogs on Gliomatosis cerebri natural history, complications, and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Natural History
- If left untreated, patients with meningioma may progress to develop focal neurological deficits, altered mental status, hydrocephalus, brain herniation, and ultimately death.
- Transformation into glioblastoma (grade 4) may occur a few years later.[1]
Complication
Common complications of gliomatosis cerebri include:[1]
- Brain herniation
- Hydrocephalus
- Coma
- Metastasis
- Recurrence
- Side effects of radiation therapy
- Side effects of chemotherapy
Prognosis
Prognosis of gliomatosis cerebri is generally poor, and the 5-year survival rate of patients with treatment is approximately 17.7%.[2][3]
The median survival time of gliomatosis cerebri is 14 months.[4]
Medial survival of patients who were treated with whole brain radiotherapy alone is 13.7 months (range 1–35), whereas those who were treated with combined whole brain radiation therapy and chemotherapy have a median survival of 26.14 months (range 6–42).[5]
The prognosis of gliomatosis cerebri depends on the following:[4][6]
- Resectibility of the tumor mass
- Age of the patient
- Age < 10 year is associated with worse prognosis.
- Gender of the patient
- Males are associated with a better prognosis than females.
- Predominant cell
- Oligodendroglial type of gliomatosis cerebri have a better prognosis.
- Location of tumor
- Infratentorial tumor is associated with shorter survival.
- Size of the tumor
- Stage of the cancer
- Primary diagnosis vs. recurrence
References
- ↑ 1.0 1.1 Treatment and prognosis of gliomatosis cerebri. Dr Henry Knipe and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/gliomatosis-cerebri
- ↑ Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T (2010). "Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases". Neurosurg Rev. 34 (2): 197–208. doi:10.1007/s10143-010-0306-1. PMID 21301914.
- ↑ Ross IB, Robitaille Y, Villemure JG, Tampieri D (1991). "Diagnosis and management of gliomatosis cerebri: recent trends". Surg Neurol. 36 (6): 431–40. PMID 1759182.
- ↑ 4.0 4.1 Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB; et al. (2002). "Gliomatosis cerebri: molecular pathology and clinical course". Ann Neurol. 52 (4): 390–9. doi:10.1002/ana.10297. PMID 12325066.
- ↑ Rajz GG, Nass D, Talianski E, Pfeffer R, Spiegelmann R, Cohen ZR (2012). "Presentation patterns and outcome of gliomatosis cerebri". Oncol Lett. 3 (1): 209–213. doi:10.3892/ol.2011.445. PMC 3362440. PMID 22740882.
- ↑ Brandão RA, de Carvalho GT, de Azeredo Coutinho CA, Christo PP, Santiago CF, Santos Mdo C; et al. (2011). "Gliomatosis cerebri: diagnostic considerations in three cases". Neurol India. 59 (1): 122–5. doi:10.4103/0028-3886.76892. PMID 21339680.